Small bowel bacterial overgrowth
Small bowel bacterial overgrowth is a syndrome of lower gastrointestinal symptoms that occurs in the settings such as gastrointestinal anatomic abnormalities (such as surgically created blind loops) or abnormal small intestinal motility (diabetic neuropathy).[1]
Small bowel bacterial overgrowth and Irritable bowel syndrome
More controversial is the connection between bacterial overgrowth and irritable bowel syndrome.[2] [3] Between 10% and 80% of patients with irritable bowel syndrome have bacterial overgrowth as detected by the lactulose H2 breath test.[2] However, the accuracy of the lactulose H2 breath test is disputed.[2]
The intestine is colonised with bacteria (also termed the gut flora). In studies from the one research group found that 78% to 84% of patients with IBS had bacterial overgrowth. In patients with evidence of bacterial overgrowth, those treated with neomycin had a >/= 35% reduction in clinical response (ie, improvement) compared with an 11% reduction in patients on placebo.[4][5]
Rifaximin, a nonabsorbed oral antibiotic improved some symptoms in a randomized controlled trial of patients with irritable bowel syndrome.[6]
References
- ↑ MedlinePlus Medical Encyclopedia: Small bowel bacterial overgrowth. Retrieved on 2008-01-04.
- ↑ 2.0 2.1 2.2 Drossman DA (2006). "Treatment for bacterial overgrowth in the irritable bowel syndrome". Ann. Intern. Med. 145 (8): 626–8. PMID 17043344. [e]
- ↑ Lin HC (2004). "Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome". JAMA 292 (7): 852–8. DOI:10.1001/jama.292.7.852. PMID 15316000. Research Blogging.
- ↑ Pimentel M, Chow EJ, Lin HC (2000). "Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome". Am J Gastroenterol 95 (12): 3503–6. PMID 11151884.
- ↑ Pimentel M, Chow EJ, Lin HC (2003). "Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study". Am J Gastroenterol 98 (2): 412–9. PMID 12591062.
- ↑ Pimentel M, Park S, Mirocha J, Kane SV, Kong Y (2006). "The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial". Ann. Intern. Med. 145 (8): 557–63. PMID 17043337. [e]